AUA 2012 - 39% of patients Disease free As I mentioned in an earlier post, Endo wouldn't be putting Urocidin and Morales (the inventor of BCG) out in the public eye for a second straight year of they were getting cold feet....on the contrary.
Here is an excerpt of the abstract on what Dr. Morales will be presenting. Sure looks good to me....and is yet another use of this drug....
"Results
14% (18/129) of patients received MCC within 24 hours of surgery (32
instillations total); 12% (16/129) received MCC on the same day of
surgery (28 instillations total). Adverse events (AEs) were
experienced by 28% (5/18) of patients following 16% (5/32) of
instillations (all in different patients and all when MCC was given on
the day of surgery). In 4 of these 5 instillations, AEs consisted of
hematuria, urinary frequency, dysuria, and suprapubic cramps. All were
mild to moderate in severity and not considered treatment related. One
patient experienced rigor, nausea, and headache with moderate severity
after 1 instillation (possibly related to MCC). No AEs resulted in
treatment discontinuation. 3 of the 5 patients received an
instillation on the same day of surgery at another time without
experiencing AEs. 39% (7/18) of the patients were disease free at 1
year."